Base de dados : MEDLINE
Pesquisa : H01.158.273.343.750 [Categoria DeCS]
Referências encontradas : 10493 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1050 ir para página                         

  1 / 10493 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29363349
[Au] Autor:Van Donge T; Mian P; Tibboel D; Van Den Anker J; Allegaert K
[Ad] Endereço:a Intensive Care and Department of Paediatric Surgery , Erasmus MC-Sophia Children's Hospital , Rotterdam , The Netherlands.
[Ti] Título:Drug metabolism in early infancy: opioids as an illustration.
[So] Source:Expert Opin Drug Metab Toxicol;14(3):287-301, 2018 Mar.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Drug dosing in infants frequently depends on body weight as a crude indicator for maturation. Fentanyl (metabolized by Cytochrome P450 3A4) and morphine (glucuronidated by UDP-glucuronosyltransferase-2B7) served as model drugs to provide insight in maturation patterns of these enzymes and provide understanding of the impact of non-maturational factors to optimize dosing in infants. Areas covered: Systematic searches on metabolism and population pharmacokinetic (Pop-PK) models for fentanyl and morphine were performed. Pre- and post-model selection criteria were applied to assess and evaluate the validity of these models. It was observed that maturational changes have been rather well investigated, be it with variability in the maturational function estimates. The same holds true for Pop-PK models, where non-maturational covariates have also been reported (pharmacogenetics, disease state or external influences), although less incorporated in the PK models and with limited knowledge on mechanisms involved. Expert opinion: PK models for fentanyl and morphine are currently available. Consequently, we suggest that researchers should not continue to develop new models, but should investigate whether collected data fit in already existing models and provide additional value concerning the impact of (non)-maturational factors like drug-drug interactions or pharmacogenetics.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Fentanila/administração & dosagem
Morfina/administração & dosagem
[Mh] Termos MeSH secundário: Fatores Etários
Analgésicos Opioides/farmacocinética
Peso Corporal
Citocromo P-450 CYP3A/metabolismo
Relação Dose-Resposta a Droga
Fentanila/farmacocinética
Glucuronosiltransferase/metabolismo
Seres Humanos
Lactente
Modelos Biológicos
Morfina/farmacocinética
Farmacogenética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Opioid); 76I7G6D29C (Morphine); EC 1.14.13.67 (CYP3A4 protein, human); EC 1.14.14.1 (Cytochrome P-450 CYP3A); EC 2.4.1.- (UGT2B7 protein, human); EC 2.4.1.17 (Glucuronosyltransferase); UF599785JZ (Fentanyl)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1432595


  2 / 10493 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29345153
[Au] Autor:Ornoy A; Koren G
[Ad] Endereço:a Laboratory of Teratology, Department of Medical Neurobiology , Hebrew University Hadassah Medical School , Jerusalem , Israel.
[Ti] Título:Selective serotonin reuptake inhibitor use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects.
[So] Source:Expert Opin Drug Metab Toxicol;14(3):247-259, 2018 Mar.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Possible negative effects of selective serotonin reuptake inhibitors (SSRIs) in pregnancy relate to congenital anomalies, negative perinatal events and neurodevelopmental outcome. Many studies are confounded by the underlying maternal disease and by pharmacogenetic and pharmacokinetic differences of these drugs. Areas covered: The possible interactions of SSRIs and serotonin and norepinephrine reuptake inhibitors with other drugs and the known effects of SSRIs on congenital anomalies, perinatal and neurodevelopmental outcome. Expert opinion: SSRIs should be given with caution when combined with other drugs that are metabolized by cytochrome P450 enzymes. SSRIs apparently increase the rate of severe cardiac malformations, induce neonatal adaptation problems in up to 30% of the offspring, increase the rate of persistent pulmonary hypertension of the newborn and possibly slightly increase the rate of prematurity and low birth weight. Most neurodevelopmental follow up studies did not find significant cognitive impairments except some transient gross motor delay, slight impairment of language abilities and possibly behavioral changes. The literature on the possible association of SSRIs with autism spectrum disorder is inconsistent; if an association exists, it is apparently throughout pregnancy. The risk associated with treatment discontinuation seems to outweigh the risk of treatment, as severe maternal depression may negatively affect the child's development. If needed, treatment should continue in pregnancy with the minimal effective dose.
[Mh] Termos MeSH primário: Depressão/tratamento farmacológico
Complicações na Gravidez/tratamento farmacológico
Inibidores da Captação de Serotonina/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Interações Medicamentosas
Feminino
Seres Humanos
Recém-Nascido
Farmacogenética
Gravidez
Efeitos Tardios da Exposição Pré-Natal/epidemiologia
Inibidores da Captação de Serotonina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Serotonin Uptake Inhibitors)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180119
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1430139


  3 / 10493 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29181932
[Au] Autor:Aambø A; Klemsdal TO
[Ti] Título:Cardiovascular disease and diabetes in patients with African or Asian background.
[Ti] Título:Kardiovaskulær sykdom og diabetes ved afrikansk eller asiatisk bakgrunn..
[So] Source:Tidsskr Nor Laegeforen;137(22), 2017 11 28.
[Is] ISSN:0807-7096
[Cp] País de publicação:Norway
[La] Idioma:eng; nor
[Ab] Resumo:BACKGROUND: Population groups of different ancestry appear to have varying prevalence of diabetes, different risks of developing cardiovascular disease and different responses to certain drugs that are used for these conditions. We wished to review the literature in this field. MATERIAL AND METHOD: We have performed searches in several databases for systematic review articles published from the year 2000 onwards, and supplemented these with articles from reference lists, our own literature archives and a pyramid search in the Norwegian Electronic Health Library database. Altogether 37 articles were included. RESULTS: With regard to diagnosed diabetes, the prevalence of coronary heart disease and stroke varies among groups of South Asian, East Asian, African and European ancestry. In patients of South Asian ancestry, the risk of coronary heart disease appears to be twice that of Europeans, and the disease occurs 5­10 years earlier. The prevalence of stroke is especially high in persons of African ancestry. Risk factors such as dyslipidemia and hypertension are distributed differently among these groups. The therapeutic response to drugs such as beta blockers, ACE inhibitors and various statins differs; for example, statin doses in Asians may often be halved in relation to those used for Caucasians, and ACE inhibitors are not recommended as monotherapy for hypertension in persons of African ancestry. These differences are partly attributable to variations in genetic disposition. INTERPRETATION: The findings are clinically significant ­ better insight in this field enables optimal tailoring of treatment for each patient, with more rapid achievement of goals and reduced risk of adverse effects. The recommendations given in this article are consistent with and complement the Directorate of Health's revised guidelines for the treatment of diabetes.
[Mh] Termos MeSH primário: Grupo com Ancestrais do Continente Africano/genética
Anti-Hipertensivos/farmacologia
Grupo com Ancestrais do Continente Asiático/genética
Doenças Cardiovasculares/etnologia
Diabetes Mellitus/etnologia
Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia
[Mh] Termos MeSH secundário: Anti-Hipertensivos/administração & dosagem
Doenças Cardiovasculares/tratamento farmacológico
Doenças Cardiovasculares/epidemiologia
Diabetes Mellitus/tratamento farmacológico
Diabetes Mellitus/epidemiologia
Grupo com Ancestrais do Continente Europeu/genética
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Farmacogenética
Acidente Vascular Cerebral/tratamento farmacológico
Acidente Vascular Cerebral/epidemiologia
Acidente Vascular Cerebral/etnologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.16.0680


  4 / 10493 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448657
[Au] Autor:Drögemöller BI; Monzon JG; Bhavsar AP; Borrie AE; Brooks B; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Aminkeng F; Amstutz U; Hildebrand CA; Gunaretnam EP; Critchley C; Chen Z; Brunham LR; Hayden MR; Ross CJD; Gelmon KA; Carleton BC
[Ad] Endereço:Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
[Ti] Título:Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
[So] Source:JAMA Oncol;3(11):1558-1562, 2017 Nov 01.
[Is] ISSN:2374-2445
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Cisplatin-induced ototoxic effects are an important complication that affects testicular cancer survivors as a consequence of treatment. The identification of genetic variants associated with this adverse drug reaction will further our mechanistic understanding of its development and potentially lead to strategies to prevent ototoxic effects. Objective: To identify the genetic variants associated with cisplatin-induced ototoxic effects in adult testicular cancer patients. Design, Setting, and Participants: This retrospective study was performed by the Canadian Pharmacogenomics Network for Drug Safety using patients recruited from 5 adult oncology treatment centers across Canada. Male patients who were 17 years or older, diagnosed with germ cell testicular cancer, and previously treated with cisplatin-based chemotherapy were recruited from July 2009 to April 2013 using active surveillance methodology. Cisplatin-induced ototoxic effects were independently diagnosed by 2 audiologists. Patients were genotyped for 7907 variants using a custom pharmacogenomic array. Logistic regression was used to identify genetic variants that were significantly associated with ototoxic effects. The validity of these findings was confirmed through independent replication and cell-based functional assays. Exposures: Cisplatin-based chemotherapy. Main Outcomes and Measures: Cisplatin-induced ototoxic effects. Results: After exclusions, 188 patients (median [interquartile range] age, 31 [24-39] years) were enrolled in this study to form the discovery and replication cohorts. Association and fine-mapping analyses identified a protein-coding variant, rs4788863 in SLC16A5, that was associated with protection against cisplatin-induced ototoxic effects in 2 independent cohorts (combined cohort: odds ratio, 0.06; 95% CI, 0.02-0.22; P = 2.17 × 10-7). Functional validation of this transporter gene revealed that in vitro SLC16A5-silencing altered cellular responses to cisplatin treatment, supporting a role for SLC16A5 in the development of cisplatin-induced ototoxic effects. These results were further supported by the literature, which provided confirmatory evidence for the role that SLC16A5 plays in hearing. Conclusions and Relevance: This study has identified a novel association between protein-coding variation in SLC16A5 and cisplatin-induced ototoxic effects. These findings have provided insight into the molecular mechanisms of this adverse drug reaction in adult patients with germ cell testicular cancer. Given that previous studies have shown that cimetidine, an SLC16A5-inhibitor, prevents murine cisplatin-induced ototoxic effects, the findings from this study have important implications for otoprotectant strategies in humans.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Cisplatino/efeitos adversos
Perda Auditiva/induzido quimicamente
Perda Auditiva/genética
Transportadores de Ácidos Monocarboxílicos/genética
Variantes Farmacogenômicos
Neoplasias Testiculares/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Canadá
Relação Dose-Resposta a Droga
Predisposição Genética para Doença
Células HeLa
Perda Auditiva/diagnóstico
Perda Auditiva/metabolismo
Seres Humanos
Modelos Logísticos
Masculino
Transportadores de Ácidos Monocarboxílicos/efeitos dos fármacos
Transportadores de Ácidos Monocarboxílicos/metabolismo
Farmacogenética
Testes Farmacogenômicos
Fenótipo
Interferência de RNA
Estudos Retrospectivos
Fatores de Risco
Transfecção
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Monocarboxylic Acid Transporters); 0 (SLC16A5 protein, human); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1001/jamaoncol.2017.0502


  5 / 10493 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29337087
[Au] Autor:Yan M; Li D; Zhao G; Li J; Niu F; Li B; Chen P; Jin T
[Ad] Endereço:Key Laboratory of Resource Biology and Biotechnology in Western China, Northwest University, Ministry of Education, Xi'an, Shaanxi 710069, China; College of Life Science, Northwest University, Xi'an, Shaanxi 710069, China.
[Ti] Título:Genetic polymorphisms of pharmacogenomic VIP variants in the Yi population from China.
[So] Source:Gene;648:54-62, 2018 Mar 30.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Drug response and target therapeutic dosage are different among individuals. The variability is largely genetically determined. With the development of pharmacogenetics and pharmacogenomics, widespread research have provided us a wealth of information on drug-related genetic polymorphisms, and the very important pharmacogenetic (VIP) variants have been identified for the major populations around the world whereas less is known regarding minorities in China, including the Yi ethnic group. Our research aims to screen the potential genetic variants in Yi population on pharmacogenomics and provide a theoretical basis for future medication guidance. MATERIALS AND METHODS: In the present study, 80 VIP variants (selected from the PharmGKB database) were genotyped in 100 unrelated and healthy Yi adults recruited for our research. Through statistical analysis, we made a comparison between the Yi and other 11 populations listed in the HapMap database for significant SNPs detection. Two specific SNPs were subsequently enrolled in an observation on global allele distribution with the frequencies downloaded from ALlele FREquency Database. Moreover, F-statistics (Fst), genetic structure and phylogenetic tree analyses were conducted for determination of genetic similarity between the 12 ethnic groups. RESULTS: Using the χ2 tests, rs1128503 (ABCB1), rs7294 (VKORC1), rs9934438 (VKORC1), rs1540339 (VDR) and rs689466 (PTGS2) were identified as the significantly different loci for further analysis. The global allele distribution revealed that the allele "A" of rs1540339 and rs9934438 were more frequent in Yi people, which was consistent with the most populations in East Asia. F-statistics (Fst), genetic structure and phylogenetic tree analyses demonstrated that the Yi and CHD shared a closest relationship on their genetic backgrounds. Additionally, Yi was considered similar to the Han people from Shaanxi province among the domestic ethnic populations in China. CONCLUSIONS: Our results demonstrated significant differences on several polymorphic SNPs and supplement the pharmacogenomic information for the Yi population, which could provide new strategies for optimizing clinical medication in accordance with the genetic determinants of drug toxicity and efficacy.
[Mh] Termos MeSH primário: Grupo com Ancestrais do Continente Asiático/genética
Genética Populacional/métodos
Farmacogenética/métodos
Polimorfismo de Nucleotídeo Único
[Mh] Termos MeSH secundário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética
Adulto
Grupo com Ancestrais do Continente Asiático/etnologia
China
Ciclo-Oxigenase 2/genética
Grupos Étnicos/classificação
Grupos Étnicos/genética
Frequência do Gene
Genótipo
Seres Humanos
Filogenia
Receptores de Calcitriol/genética
Vitamina K Epóxido Redutases/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Receptors, Calcitriol); 0 (VDR protein, human); EC 1.14.99.1 (Cyclooxygenase 2); EC 1.14.99.1 (PTGS2 protein, human); EC 1.17.4.4 (VKORC1 protein, human); EC 1.17.4.4 (Vitamin K Epoxide Reductases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  6 / 10493 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29271660
[Au] Autor:Maughan A; Ogbuagu O
[Ad] Endereço:a Yale AIDS Program, Section of Infectious Diseases , Yale University School of Medicine , New Haven , CT , USA.
[Ti] Título:Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection.
[So] Source:Expert Opin Drug Metab Toxicol;14(2):219-227, 2018 Feb.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Treatments for hepatitis C virus (HCV) infection have advanced rapidly in the last decade. Pegylated interferon alpha 2a (PEG-IFN alpha 2a) alone, in combination with ribavirin and with or without direct acting antivirals (DAAs) is modestly effective in the treatment of chronic HCV infection. Areas covered: The review describes the chemistry, pharmacokinetic and pharmacodynamic properties, clinical efficacy, safety and drug-drug interaction profiles of PEG-IFN alpha 2a. Expert opinion: Despite the availability of DAAs and its formidable toxicity profile, PEG-IFN alpha 2a retains a role for the treatment of acute HCV and chronic HCV infection in resource limited settings and for end-stage renal disease patients and others who cannot access DAAs or are DAA-ineligible. Knowledge of pharmacogenetic profiles which favor successful treatment outcomes with IFN-based therapies may allow for selection of best candidates for the regimen.
[Mh] Termos MeSH primário: Antivirais/administração & dosagem
Hepatite C Crônica/tratamento farmacológico
Interferon-alfa/administração & dosagem
Polietilenoglicóis/administração & dosagem
[Mh] Termos MeSH secundário: Antivirais/efeitos adversos
Antivirais/farmacocinética
Interações Medicamentosas
Quimioterapia Combinada
Hepacivirus/efeitos dos fármacos
Hepatite C Crônica/virologia
Seres Humanos
Interferon-alfa/efeitos adversos
Interferon-alfa/farmacocinética
Falência Renal Crônica/fisiopatologia
Seleção de Pacientes
Farmacogenética
Polietilenoglicóis/efeitos adversos
Polietilenoglicóis/farmacocinética
Proteínas Recombinantes/administração & dosagem
Proteínas Recombinantes/efeitos adversos
Proteínas Recombinantes/farmacocinética
Ribavirina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Interferon-alpha); 0 (Recombinant Proteins); 30IQX730WE (Polyethylene Glycols); 49717AWG6K (Ribavirin); Q46947FE7K (peginterferon alfa-2a)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1421173


  7 / 10493 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470340
[Au] Autor:Iyer PM; Karthikeyan S; Sanjay Kumar P; Krishnan Namboori PK
[Ad] Endereço:Department of Electronics and Communication Engineering, M.Tech-Biomedical Engineering Amrita School of Engineering, AMRITA Vishwa Vidyapeetham Amrita University, Amritanagar, Ettimadai, Coimbatore, Tamil Nadu, 641112, India.
[Ti] Título:Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
[So] Source:Funct Integr Genomics;17(4):375-385, 2017 Jul.
[Is] ISSN:1438-7948
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The proneness of diseases and susceptibility towards drugs vary from person to person. At present, there is a strong demand for the personalization of drugs. The genetic signature behind proneness of the disease has been studied through a comprehensive 'octopodial approach'. All the genetic variants included in the approach have been introduced. The breast cancer associated with BRCA1 mutation has been taken as the illustrative example to introduce all these factors. The genetic variants associated with the drug action of tamoxifen have been fully illustrated in the manuscript. The design of a new personalized anti-breast cancer drug has been explained in the third phase. For the design of new personalized drugs, a metabolite of anti-cancer drug chlorambucil has been taken as the template. The design of drug has been made with respect to the protein 1T15 of BRCA1 gene corresponding to the genetic signature of rs28897696.
[Mh] Termos MeSH primário: Neoplasias da Mama/tratamento farmacológico
Desenho de Drogas
Predisposição Genética para Doença
Farmacogenética/métodos
Medicina de Precisão/métodos
[Mh] Termos MeSH secundário: Antineoplásicos/química
Antineoplásicos/farmacologia
Antineoplásicos/uso terapêutico
Proteína BRCA1/química
Proteína BRCA1/genética
Neoplasias da Mama/genética
Clorambucila/química
Clorambucila/farmacologia
Feminino
Seres Humanos
Polimorfismo de Nucleotídeo Único
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (BRCA1 Protein); 0 (BRCA1 protein, human); 18D0SL7309 (Chlorambucil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1007/s10142-017-0559-7


  8 / 10493 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470827
[Au] Autor:Nuntamool N; Ngamsamut N; Vanwong N; Puangpetch A; Chamnanphon M; Hongkaew Y; Limsila P; Suthisisang C; Wilffert B; Sukasem C
[Ad] Endereço:Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
[Ti] Título:Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents.
[So] Source:Basic Clin Pharmacol Toxicol;121(4):316-324, 2017 Oct.
[Is] ISSN:1742-7843
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to evaluate the association of pharmacogenomic factors and clinical outcome in autistic children and adolescents who were treated with risperidone for long periods. Eighty-two autistic subjects diagnosed with DSM-IV and who were treated with risperidone for more than 1 year were recruited. Pharmacogenomics and clinical outcome (CGI-I, aggressive, overactivity and repetitive score) were evaluated. Almost all patients showed stable symptoms on aggressive behaviour (89.02%), overactivity (71.95%), repetitive (70.89%) behaviour and all clinical symptoms (81.71%). Only 4.48% of patients showed minimally worse CGI-I score. Patients in the non-stable symptom group had DRD2 Taq1A non-wild-type (TT and CT) frequencies higher than the clinically stable group (p = 0.04), whereas other gene polymorphisms showed no significant association. Haplotype ACCTCAT (rs6311, rs1045642, rs1128503, rs1800497, rs4436578, rs1799978, rs6280) showed a significant association with non-stable clinical outcome (χ  = 6.642, p = 0.010). Risperidone levels showed no association with any clinical outcome. On the other hand, risperidone dose, 9-OH risperidone levels and prolactin levels were significantly higher in the non-stable compared to the stable symptom group (p = 0.013, p = 0.044, p = 0.030). Increased appetite was the most common adverse drug reaction and associated with higher body-weight, whereas it was not significantly associated with genetic variations and non-genetic information. In conclusion, risperidone showed efficacy to control autism, especially aggressive symptoms in long-term treatment. However, Taq1A T - carrier of dopamine 2 receptor gene - is associated with non-stable response in risperidone-treated patients. This study supports pharmacogenomics testing for personalized therapy with risperidone in autistic children and adolescents.
[Mh] Termos MeSH primário: Comportamento do Adolescente/efeitos dos fármacos
Transtorno Autístico/tratamento farmacológico
Comportamento Infantil/efeitos dos fármacos
Antagonistas de Dopamina/administração & dosagem
Receptores de Dopamina D2/efeitos dos fármacos
Receptores de Dopamina D2/genética
Risperidona/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Fatores Etários
Agressão/efeitos dos fármacos
Transtorno Autístico/diagnóstico
Transtorno Autístico/genética
Transtorno Autístico/psicologia
Distribuição de Qui-Quadrado
Criança
Estudos Transversais
Manual Diagnóstico e Estatístico de Transtornos Mentais
Antagonistas de Dopamina/efeitos adversos
Esquema de Medicação
Feminino
Frequência do Gene
Haplótipos
Heterozigoto
Homozigoto
Seres Humanos
Masculino
Farmacogenética
Variantes Farmacogenômicos
Estudos Prospectivos
Receptores de Dopamina D2/metabolismo
Fatores de Risco
Risperidona/efeitos adversos
Tailândia
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DRD2 protein, human); 0 (Dopamine Antagonists); 0 (Receptors, Dopamine D2); L6UH7ZF8HC (Risperidone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/bcpt.12803


  9 / 10493 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457163
[Au] Autor:Singh AB; Bousman CA
[Ad] Endereço:From the School of Medicine, IMPACT Strategic Research Centre, Deakin University, Geelong, Victoria, Australia; and Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
[Ti] Título:Antidepressant Pharmacogenetics.
[So] Source:Am J Psychiatry;174(5):417-418, 2017 05 01.
[Is] ISSN:1535-7228
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antidepressivos
Farmacogenética
[Mh] Termos MeSH secundário: Depressão
Seres Humanos
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Antidepressive Agents)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1176/appi.ajp.2017.17020173


  10 / 10493 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29226732
[Au] Autor:Motta I; Calcagno A; Bonora S
[Ad] Endereço:a Unit of Infectious Diseases, Department of Medical Sciences , University of Torino , Torino , Italy.
[Ti] Título:Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
[So] Source:Expert Opin Drug Metab Toxicol;14(1):59-82, 2018 Jan.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: WHO global strategy is to end tuberculosis epidemic by 2035. Pharmacokinetic and pharmacogenetic studies are increasingly performed and might confirm their potential role in optimizing treatment outcome in specific settings and populations. Insufficient drug exposure seems to be a relevant factor in tuberculosis outcome and for the risk of phenotypic resistance. Areas covered: This review discusses available pharmacokinetic and pharmacogenetic data of first and second-line antitubercular agents in relation to efficacy and toxicity. Pharmacodynamic implications of optimized drugs and new options regimens are reviewed. Moreover a specific session describes innovative investigations on drug penetration. Expert opinion: The optimal use of available antitubercular drugs is paramount for tuberculosis control and eradication. Whilst trials are still on-going, higher rifampicin doses should be reserved to treatment for tubercular meningitis. Therapeutic Drug Monitoring with limiting sampling strategies is advised in patients at risk of failure or with slow treatment response. Further studies are needed in order to provide definitive recommendations of pharmacogenetic-based individualization: however lower isoniazid doses in NAT2 slow acetylators and higher rifampicin doses in individuals with SLCO1B1 loss of function genes are promising strategies. Finally in order to inform tailored strategies we need more data on tissue drug penetration and pharmacological modelling.
[Mh] Termos MeSH primário: Antituberculosos/administração & dosagem
Farmacogenética
Tuberculose/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antituberculosos/efeitos adversos
Antituberculosos/farmacocinética
Relação Dose-Resposta a Droga
Monitoramento de Medicamentos/métodos
Farmacorresistência Bacteriana
Seres Humanos
Isoniazida/administração & dosagem
Isoniazida/farmacocinética
Modelos Biológicos
Rifampina/administração & dosagem
Rifampina/farmacocinética
Tuberculose/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antitubercular Agents); V83O1VOZ8L (Isoniazid); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1416093



página 1 de 1050 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde